We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+34.71%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.61B
AUM Growth
+$411M
Cap. Flow
+$88.5M
Cap. Flow %
5.49%
Top 10 Hldgs %
79.5%
Holding
39
New
7
Increased
9
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
GH icon
Guardant Health
GH
+$25M
2
TXG icon
10x Genomics
TXG
+$21.1M
3
DNLI icon
Denali Therapeutics
DNLI
+$16M
4
LAB icon
Standard BioTools
LAB
+$15.1M
5
RLAY icon
Relay Therapeutics
RLAY
+$11.9M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$50.4M
2
BLFS icon
BioLife Solutions
BLFS
+$19.6M
3
GPCR icon
Structure Therapeutics
GPCR
+$15.5M
4
EXAS
Exact Sciences
EXAS
+$4.92M
5
RVMD icon
Revolution Medicines
RVMD
+$4.59M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
26
Incyte
INCY
$24.2B
$9.88M 0.61%
100,000
– –
DGX icon
27
Quest Diagnostics
DGX
$25.7B
$8.68M 0.54%
+50,000
New +$9.1M
TSHA icon
28
Taysha Gene Therapies
TSHA
$1.68B
$8.25M 0.51%
+1,500,000
New +$7.28M
PACB icon
29
Pacific Biosciences
PACB
$435M
$7.9M 0.49%
4,223,767
+3,500,000
+484% +$6.73M
LEGN icon
30
Legend Biotech
LEGN
$3.59B
$4.67M 0.29%
+215,000
New +$6.16M
BBOT
31
BridgeBio Oncology
BBOT
$648M
$3.53M 0.22%
282,312
– –
ABSI icon
32
Absci
ABSI
$1.32B
$3.4M 0.21%
973,260
– –
CTNM
33
Contineum Therapeutics
CTNM
$579M
$1.7M 0.11%
148,333
– –
GLUE icon
34
Monte Rosa Therapeutics
GLUE
$1.4B
$1.35M 0.08%
86,014
– –
IPSC icon
35
Century Therapeutics
IPSC
$364M
$1.22M 0.08%
1,228,190
– –
RXRX icon
36
Recursion Pharmaceuticals
RXRX
$1.59B
$676K 0.04%
165,323
– –
DNA icon
37
Ginkgo Bioworks
DNA
$528M
$303K 0.02%
36,493
– –
TNYA icon
38
Tenaya Therapeutics
TNYA
$161M
$258K 0.02%
361,969
– –
EXAS
39
DELISTED
Exact Sciences
EXAS
– –
-90,000
Closed -$4.92M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q4 2025 Portfolio in Review

As of Q4 2025, Casdin Capital held 39 positions worth $1.61B, up 34% from $1.2B the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Casdin Capital deployed $88.5M of net new capital in Q4 2025, opening 7 new positions and adding to 9 existing holdings. Its largest new stake was 10x Genomics: 1,400,000 shares worth $22.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Avidity Biosciences, an estimated $50.4M trimmed.

  • Casdin Capital's largest Q4 2025 buy was 10x Genomics: 1,400,000 shares worth $22.8M.
  • Casdin Capital added most to Guardant Health in Q4 2025, an estimated $25M increase.
  • Casdin Capital's biggest Q4 2025 reduction was Avidity Biosciences, cutting an estimated $50.4M.
  • Casdin Capital fully exited Exact Sciences in Q4 2025, selling an estimated $4.92M.
  • Casdin Capital's ten largest holdings make up 79% of its $1.61B portfolio in Q4 2025.
  • Casdin Capital opened 7 new positions and closed 1 in Q4 2025.
  • Casdin Capital's portfolio value rose 34% quarter-over-quarter to $1.61B.

Based on Casdin Capital's 13F filing for Q4 2025, filed 17 Feb 2026.